Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab

Eur J Cancer. 2020 Jul:133:22-24. doi: 10.1016/j.ejca.2020.04.008. Epub 2020 May 15.

Authors

Yoko Tsukita¹, Eisaku Miyauchi², Masahide Fukudo³, Takaaki Sasaki⁴, Masakazu Ichinose¹

Affiliations

¹ Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, 980 8574, Japan.
² Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, 980 8574, Japan. Electronic address: miyauchi@rm.med.tohoku.ac.jp.
³ Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University, Asahikawa, Japan.
⁴ Respiratory Center, Asahikawa Medical University Hospital, Asahikawa, Japan.

PMID: 32422505
DOI: 10.1016/j.ejca.2020.04.008

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / pathology
Chemical and Drug Induced Liver Injury / diagnosis*
Dose-Response Relationship, Drug
Female
Hepatitis / diagnosis
Hepatitis / etiology
Humans
Immunotherapy / adverse effects*
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Thrombocytopenia / chemically induced*
Thrombocytopenia / diagnosis

Substances

Antibodies, Monoclonal, Humanized
atezolizumab